Page 8 - Phissons Ethics Dilemma
P. 8
Projections
Sales projections indicated that by year
three all sunk costs will have been
recovered. Thereafter profit momentum
would be maintained as Proxydychromil
is introduced into new markets especially
the US and Canada. This will be followed
by introductions into other developed
markets.
If Phissons withdraws the
drug before the launch the
impact will be catastrophic.
The fear is that the share
price will collapse as
investors seek to minimise
their risk exposure.
The alternative is to launch the drug and bear the fallout from the inevitable deaths.
